歌禮制藥-B(01672.HK): 利托那韋片治療新型冠狀病毒肺炎的研究獲浙江省相關監管部門批准
格隆匯2月17日丨歌禮制藥-B(01672.HK)公佈,浙江藥監局和浙江衞生健康委員會組織專家於2020年2月15日進行了省級"治療新冠肺炎藥物應急臨牀科研攻關和創新應用"項目評審,同意開展"利托那韋片治療新型冠狀病毒肺炎的療效及安全性研究"。
公告稱,該研究由浙江大學醫學院附屬第一醫院牽頭,與公司聯合開展。利托那韋片是公司研發的口服固體片劑,與靜脈注射和口服液體制劑相比,給藥方式簡捷方便。
截至公告日期,口服ASC09複方片、利托那韋片共啟動了4個治療新型冠狀病毒肺炎的臨牀研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.